CT-2106
We are also developing a novel polyglutamate-camptothecin, CT-2106.
Linking a camptothecin to our polyglutamate
polymer renders it water soluble,
and preclinical studies suggest that it permits up to 400% more
drug to be administered without an increase in toxicity. CT-2106
as
a single agent and/or in combination with 5FU showed significantly
enhanced anti-tumor activity in several animal tumor models.
Camptothecins are an important and rapidly growing
class of anti-cancer drugs. However, like taxanes,
their full clinical benefit is limited by poor
solubility and significant toxicity. Oral
analogs such as topotecan and irinotecan are soluble,
but are less effective in combating tumors. Camptothecins
are important drugs in the treatment of advanced
colon, lung, and ovarian cancers.
We have optimized a polyglutamate camptothecin for clinical
development and filed an Investigational New Drug (IND) application
in December 2001.
CT-2106 Clinical Trials
Phase I/II and II clinical trials of CT-2106 in patients with
advanced cancers are currently underway.
See Clinical Trials
for current trials.
Posted July 18, 2005
Copyright © 2004, 2005 Cell Therapeutics, Inc.,
Seattle, WA, USA. All rights reserved. "Making cancer more treatable" is
a registered mark of CTI.
|